利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

66 条记录 (耗时 0.031 秒)

    Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
    5.
    发明授权
    Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis 失效
    使用1,6-萘啶酮衍生物治疗肺血栓形成

    公开(公告)号：US4698341A

    公开(公告)日：1987-10-06

    申请号：US753758

    申请日：1985-07-11

    申请人： Gerhard Satzinger ,  Johannes Hartenstein ,  Karl Mannhardt ,  Jurgen Kleinschroth ,  Manfred Herrmann ,  Edgar Fritschi ,  Horst-Dietmar Tauschel ,  Bernd Wagner ,  Gunter Wolf

    发明人： Gerhard Satzinger ,  Johannes Hartenstein ,  Karl Mannhardt ,  Jurgen Kleinschroth ,  Manfred Herrmann ,  Edgar Fritschi ,  Horst-Dietmar Tauschel ,  Bernd Wagner ,  Gunter Wolf

    IPC分类号： C07D211/90 ,  C07D471/04 ,  A61K31/455 ,  A61K31/535

    CPC分类号： C07D471/04 ,  C07D211/90

    摘要： New 1,6-naphthyridinone derivatives of the formula I ##STR1## are herein described wherein R.sup.1 represents an unsubstituted or substituted aromatic or heteroaromatic ring;R.sup.2 is hydrogen, a straight-chained or branched alkyl, alkoxyalkyl, or a substituted or unsubstituted aminoalkyl group with up to ten carbon atoms;R.sup.3 is hydrogen, a straight-chained or branched alkyl group, or an alkoxycarbonyl radical with up to four carbon atoms;R.sup.4 is hydrogen, or a morpholinoethyl group;R.sup.5 is a straight-chained or branched alkyl group with up to four carbon atoms, or an amino group; andR.sup.6 is a carboxyl group, or an alkyl- or alkyloxyalkyl carbonyl radical, containing up to 12 carbon atoms and optionally interrupted by an oxygen, sulphur, or nitrogen atom;as well as optionally the pharmacologically acceptable salts thereof; processes for the preparation of these derivatives and their use in the control of vascular diseases.

    摘要翻译： 本文描述了式I（I）的新的1,6-萘啶酮衍生物，其中R 1表示未取代或取代的芳族或杂芳族环; R2是氢，直链或支链烷基，烷氧基烷基或具有至多10个碳原子的取代或未取代的氨基烷基; R3是氢，直链或支链烷基或具有至多四个碳原子的烷氧基羰基; R4是氢或吗啉代乙基; R5是具有至多4个碳原子的直链或支链烷基或氨基; 并且R 6是含有至多12个碳原子并任选被氧，硫或氮原子中断的羧基或烷基 - 或烷氧基烷基羰基; 以及任选地其药理学上可接受的盐; 这些衍生物的制备方法及其在血管疾病控制中的应用。

    3-aryl-3-pyrroline derivatives
    6.
    发明授权
    3-aryl-3-pyrroline derivatives 失效
    3-芳基-3-吡咯啉衍生物

    公开(公告)号：US4626546A

    公开(公告)日：1986-12-02

    申请号：US637351

    申请日：1984-08-03

    申请人： Gerhard Satzinger ,  Karl Mannhardt ,  Johannes Hartenstein ,  Manfred Herrmann ,  Edgar Fritschi ,  Wolfgang Steinbrecher

    发明人： Gerhard Satzinger ,  Karl Mannhardt ,  Johannes Hartenstein ,  Manfred Herrmann ,  Edgar Fritschi ,  Wolfgang Steinbrecher

    IPC分类号： A61K31/40 ,  A61P9/08 ,  A61P9/10 ,  C07D207/20

    CPC分类号： C07D207/20

    摘要： The invention is concerned with partially new compounds of the general formula ##STR1## wherein R.sup.1 is a hydrogen atom or an alkyl group with up to four carbon atoms and R.sup.2 a substituted phenyl radical and the pharmacologically acceptable salts thereof.The compounds can be prepared according to known procedures and show surprisingly a cardiovascular efficacy. They are capable of decompensating cardiac insufficiencies to a large extent. In addition to the new compounds, claim is also made for pharmaceutical compositions which contain compounds according to the general formula and their application for controlling cardiac and vascular diseases.

    摘要翻译： 本发明涉及通式“IMAGE”的部分新化合物，其中R 1为氢原子或具有至多4个碳原子的烷基，R 2为取代的苯基及其药理学上可接受的盐。 这些化合物可以根据已知的方法制备并令人惊奇地显示出心血管功能。 它们能够在很大程度上失代偿心脏功能不全。 除了新化合物之外，还提出了含有根据通式的化合物及其用于控制​​心脏和血管疾病的应用的药物组合物。

    5,6;8,9-Tetrahydro-7H-dibenz(d,f)azonines
    10.
    发明授权
    5,6;8,9-Tetrahydro-7H-dibenz(d,f)azonines 失效
    5,6; 8,9-四氢-7H-二苯并（d，f）吖嗪

    公开(公告)号：US4415495A

    公开(公告)日：1983-11-15

    申请号：US238501

    申请日：1981-02-24

    申请人： Gerhard Satzinger ,  Manfred Herrmann ,  Edgar Fritschi ,  Heinrich Bahrmann ,  Volker Ganser ,  Bernd Wagner ,  Wolfgang Steinbrecher

    发明人： Gerhard Satzinger ,  Manfred Herrmann ,  Edgar Fritschi ,  Heinrich Bahrmann ,  Volker Ganser ,  Bernd Wagner ,  Wolfgang Steinbrecher

    IPC分类号： C07D225/06 ,  A61K31/395 ,  A61K31/485 ,  A61P9/06 ,  C07D225/08 ,  A61K31/355

    CPC分类号： C07D225/08

    摘要： The present invention provides 5,6;8,9-tetrahydro-7H-dibenz(d,f)azonine derivatives of the formula: ##STR1## wherein R.sup.1 and R.sup.2, which are the same or different, are hydrogen or halogen atoms or lower alkyl or alkoxy radicals, R.sup.3 is a hydrogen atom or a lower alkyl radical, R.sup.4 is a hydrogen atom or a lower alkyl or alkanoyl radical and n is 1 or 2; and the pharmaceutically acceptable salts thereof formed with inorganic and organic acids; but excluding 6-benzyl-2,12-dimethoxy-1-hydroxy-7-methyl-5,6;8,9-tetrahydro-7H-dibenz(d,f)azonine in which case R.sup.1, R.sup.2 and R.sup.4 are hydrogen, n is 1 and R.sup.3 is methyl. The lower alkyl, alkanoyl and alkoxy radicals are straight chained or branched radicals containing 1 to 5 carbon atoms.The present invention also provides a process for the preparation of these compounds, as well as pharmaceutical compositions containing them.

    摘要翻译： 本发明提供下式的5,6,8,9-四氢-7H-二苯并（d，f）吖嗪衍生物：其中R 1和R 2相同或不同，为氢或卤原子或更低级 烷基或烷氧基，R3是氢原子或低级烷基，R4是氢原子或低级烷基或烷酰基，n是1或2; 和其与无机酸和有机酸形成的药学上可接受的盐; 但不包括6-苄基-2,12-二甲氧基-1-羟基-7-甲基-5,6; 8,9-四氢-7H-二苯并吖嗪（d，f）吖嗪，其中R1，R2和R4是氢 ，n为1，R 3为甲基。 低级烷基，烷酰基和烷氧基是含有1至5个碳原子的直链或支链基团。 本发明还提供了制备这些化合物的方法以及含有它们的药物组合物。